US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
ATE300521T1
(de)
|
1996-09-25 |
2005-08-15 |
Astrazeneca Ab |
Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
|
ES2289791T3
(es)
|
1997-08-22 |
2008-02-01 |
Astrazeneca Ab |
Derivados de oxindolilquinazolina como inhibidores de la angiogenesis.
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
EP1115724A1
(en)
|
1998-09-21 |
2001-07-18 |
Shire Biochem Inc. |
Quinolizinones as integrin inhibitors
|
BR0008524A
(pt)
|
1999-02-27 |
2001-12-18 |
Boehringer Ingelheim Pharma |
Heterociclos bicìclicos, composiçõesfarmacêuticas que contêm esses compostos, seuuso e processos para a sua prerapação
|
DE19911509A1
(de)
*
|
1999-03-15 |
2000-09-21 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
RS49836B
(sr)
*
|
1999-03-31 |
2008-08-07 |
Pfizer Products Inc., |
Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
|
MXPA01012899A
(es)
*
|
1999-06-21 |
2002-07-30 |
Boehringer Ingelheim Pharma |
Heterociclos biciclicos, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
ATE377597T1
(de)
|
1999-07-09 |
2007-11-15 |
Glaxo Group Ltd |
Anilinochinazoline als protein-tyrosin- kinasehemmer
|
RU2002110461A
(ru)
*
|
1999-09-21 |
2004-03-10 |
Астразенека Аб (Se) |
Производные хиназолина и их применение в качестве фармацевтических веществ
|
SE9903544D0
(sv)
|
1999-10-01 |
1999-10-01 |
Astra Pharma Prod |
Novel compounds
|
ES2306306T3
(es)
*
|
1999-11-05 |
2008-11-01 |
Astrazeneca Ab |
Nuevos derivados de quinazolina.
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
JP4837864B2
(ja)
*
|
2000-02-09 |
2011-12-14 |
ノバルティス アーゲー |
血管形成および/またはvegf受容体チロシンキナーゼを阻害するピリジン誘導体
|
GB2359551A
(en)
|
2000-02-23 |
2001-08-29 |
Astrazeneca Uk Ltd |
Pharmaceutically active pyrimidine derivatives
|
WO2001066099A2
(en)
*
|
2000-03-06 |
2001-09-13 |
Astrazeneca Ab |
Use of quinazoline derivatives as angiogenesis inhibitors
|
US20070021392A1
(en)
*
|
2000-03-31 |
2007-01-25 |
Davis Peter D |
Divided dose therapies with vascular damaging activity
|
GB0008269D0
(en)
*
|
2000-04-05 |
2000-05-24 |
Astrazeneca Ab |
Combination chemotherapy
|
US7160889B2
(en)
*
|
2000-04-07 |
2007-01-09 |
Astrazeneca Ab |
Quinazoline compounds
|
UA73993C2
(uk)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Хіназолінові похідні для лікування пухлин та фармацевтична композиція
|
AR028948A1
(es)
|
2000-06-20 |
2003-05-28 |
Astrazeneca Ab |
Compuestos novedosos
|
EP1313727A1
(en)
*
|
2000-08-21 |
2003-05-28 |
AstraZeneca AB |
Quinazoline derivatives
|
US6656946B2
(en)
|
2000-08-26 |
2003-12-02 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6403580B1
(en)
|
2000-08-26 |
2002-06-11 |
Boehringer Ingelheim Pharma Kg |
Quinazolines, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
US6617329B2
(en)
|
2000-08-26 |
2003-09-09 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines and their use as medicaments
|
DE10042061A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE10042058A1
(de)
*
|
2000-08-26 |
2002-03-07 |
Boehringer Ingelheim Pharma |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
US6740651B2
(en)
|
2000-08-26 |
2004-05-25 |
Boehringer Ingelheim Pharma Kg |
Aminoquinazolines which inhibit signal transduction mediated by tyrosine kinases
|
US6849625B2
(en)
*
|
2000-10-13 |
2005-02-01 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
SE0003828D0
(sv)
|
2000-10-20 |
2000-10-20 |
Astrazeneca Ab |
Novel compounds
|
WO2002036587A2
(en)
|
2000-11-01 |
2002-05-10 |
Cor Therapeutics, Inc. |
Process for the production of 4-quinazolinylpiperazin-1-carboxylic acid phenylamides
|
US7019012B2
(en)
*
|
2000-12-20 |
2006-03-28 |
Boehringer Ingelheim International Pharma Gmbh & Co. Kg |
Quinazoline derivatives and pharmaceutical compositions containing them
|
DE60229046D1
(de)
*
|
2001-04-19 |
2008-11-06 |
Astrazeneca Ab |
Chinazolin derivate
|
WO2002092577A1
(en)
*
|
2001-05-14 |
2002-11-21 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU2002350105A1
(en)
|
2001-06-21 |
2003-01-08 |
Ariad Pharmaceuticals, Inc. |
Novel quinazolines and uses thereof
|
GB0126879D0
(en)
*
|
2001-11-08 |
2002-01-02 |
Astrazeneca Ab |
Combination therapy
|
GB0128109D0
(en)
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
GB0128108D0
(en)
*
|
2001-11-23 |
2002-01-16 |
Astrazeneca Ab |
Therapeutic use
|
UA81619C2
(ru)
*
|
2002-02-01 |
2008-01-25 |
Астразенека Аб |
Хиназолиновые соединения, способ их получения (варианты), фармацевтическая композиция на их основе
|
TW200813014A
(en)
*
|
2002-03-28 |
2008-03-16 |
Astrazeneca Ab |
Quinazoline derivatives
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
DE10221018A1
(de)
*
|
2002-05-11 |
2003-11-27 |
Boehringer Ingelheim Pharma |
Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
|
EP1528925B1
(en)
*
|
2002-07-09 |
2009-04-22 |
Astrazeneca AB |
Quinazoline derivatives for use in the treatment of cancer
|
CA2491191C
(en)
*
|
2002-07-15 |
2014-02-04 |
Exelixis, Inc. |
Receptor-type kinase modulators and methods of use
|
GB0217431D0
(en)
|
2002-07-27 |
2002-09-04 |
Astrazeneca Ab |
Novel compounds
|
EP1539713B1
(en)
|
2002-08-24 |
2007-12-19 |
Astrazeneca AB |
Pyrimidine derivatives as modulators of chemokine receptor activity
|
GB0221828D0
(en)
|
2002-09-20 |
2002-10-30 |
Astrazeneca Ab |
Novel compound
|
GB0223380D0
(en)
*
|
2002-10-09 |
2002-11-13 |
Astrazeneca Ab |
Combination therapy
|
KR101089462B1
(ko)
|
2002-11-04 |
2011-12-07 |
아스트라제네카 아베 |
Src 티로신 키나제 억제제로서의 퀴나졸린 유도체
|
ES2290529T3
(es)
|
2002-12-24 |
2008-02-16 |
Astrazeneca Ab |
Derivados de fosfonooxiquinazolina y su uso farmaceutico.
|
GEP20084540B
(en)
|
2003-01-14 |
2008-11-25 |
Arena Pharm Inc |
1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prpphylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
|
US7223749B2
(en)
*
|
2003-02-20 |
2007-05-29 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
SE0301569D0
(sv)
|
2003-05-27 |
2003-05-27 |
Astrazeneca Ab |
Novel compounds
|
PA8603801A1
(es)
*
|
2003-05-27 |
2004-12-16 |
Janssen Pharmaceutica Nv |
Derivados de la quinazolina
|
KR20120093411A
(ko)
*
|
2003-07-10 |
2012-08-22 |
아스트라제네카 아베 |
백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 zd6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
|
GB0316176D0
(en)
*
|
2003-07-10 |
2003-08-13 |
Astrazeneca Ab |
Combination therapy
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
GB0318423D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
DK1660057T3
(da)
|
2003-08-27 |
2012-08-20 |
Ophthotech Corp |
Kombinationsterapi til behandling af neovaskulære øjenlidelser
|
WO2005026157A1
(en)
*
|
2003-09-16 |
2005-03-24 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP4795952B2
(ja)
|
2003-09-16 |
2011-10-19 |
アストラゼネカ アクチボラグ |
チロシンキナーゼ阻害剤としてのキナゾリン誘導体
|
DE602004004553T2
(de)
*
|
2003-09-19 |
2007-10-25 |
Astrazeneca Ab |
Chinazolinderivate
|
US20070037837A1
(en)
*
|
2003-09-19 |
2007-02-15 |
Hennequin Laurent Francois A |
Quinazoline derivatives
|
AU2004276055A1
(en)
*
|
2003-09-25 |
2005-04-07 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0322409D0
(en)
*
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP4638436B2
(ja)
|
2003-09-26 |
2011-02-23 |
エグゼリクシス, インコーポレイテッド |
c−Metモジュレーターおよびその使用
|
US7456189B2
(en)
*
|
2003-09-30 |
2008-11-25 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
WO2005051906A2
(en)
|
2003-11-19 |
2005-06-09 |
Array Biopharma Inc. |
Heterocyclic inhibitors of mek and methods of use thereof
|
GB0328243D0
(en)
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Methods
|
UA83881C2
(en)
|
2003-12-18 |
2008-08-26 |
Янссен Фармацевтика Н.В. |
Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
|
WO2005066163A2
(en)
|
2004-01-05 |
2005-07-21 |
Astrazeneca Ab |
Thiophene derivatives as chk 1 inihibitors
|
US7632840B2
(en)
|
2004-02-03 |
2009-12-15 |
Astrazeneca Ab |
Quinazoline compounds for the treatment of hyperproliferative disorders
|
DK1746999T3
(da)
|
2004-05-06 |
2012-01-23 |
Warner Lambert Co |
4-phenylamino-quinazolin-6-yl-amider
|
GB0411378D0
(en)
*
|
2004-05-21 |
2004-06-23 |
Astrazeneca Ab |
Pharmaceutical compositions
|
SE0401657D0
(sv)
|
2004-06-24 |
2004-06-24 |
Astrazeneca Ab |
Chemical compounds
|
CA2573103A1
(en)
*
|
2004-07-06 |
2006-02-09 |
Angion Biomedica Corporation |
Quinazoline modulators of hepatocyte growth factor / c-met activity for the treatment of cancer
|
BRPI0514735B8
(pt)
|
2004-08-28 |
2021-05-25 |
Astrazeneca Ab |
derivados de pirimidino sulfonamida como moduladores do receptor de quimiocina.
|
GB0424339D0
(en)
*
|
2004-11-03 |
2004-12-08 |
Astrazeneca Ab |
Combination therapy
|
NI200700147A
(es)
|
2004-12-08 |
2019-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina inhibidores de cinasas dirigidos a multip
|
JO3088B1
(ar)
*
|
2004-12-08 |
2017-03-15 |
Janssen Pharmaceutica Nv |
مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
|
DE602005026865D1
(de)
|
2004-12-14 |
2011-04-21 |
Astrazeneca Ab |
Pyrazolopyrimidinverbindungen als antitumormittel
|
CN105085678B
(zh)
|
2004-12-21 |
2019-05-07 |
阿斯利康公司 |
血管生成素-2的抗体及其应用
|
KR20060079121A
(ko)
*
|
2004-12-31 |
2006-07-05 |
에스케이케미칼주식회사 |
당뇨 및 비만 치료예방에 유효한 퀴나졸린 유도체
|
DOP2006000010A
(es)
|
2005-01-10 |
2006-07-31 |
Arena Pharm Inc |
Procedimiento para preparar eteres aromáticos
|
BRPI0606793A8
(pt)
|
2005-02-04 |
2018-03-13 |
Astrazeneca Ab |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
|
AU2006217738A1
(en)
*
|
2005-02-26 |
2006-08-31 |
Astrazeneca Ab |
Quinazoline derivatives as tyrosine kinase inhibitors
|
WO2006104059A1
(ja)
*
|
2005-03-28 |
2006-10-05 |
National Institute For Materials Science |
コバルトフリーのNi基超合金
|
WO2006119674A1
(fr)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
|
CN101180279A
(zh)
*
|
2005-05-12 |
2008-05-14 |
黄文林 |
一种作为抗肿瘤药物应用的酪氨酸激酶抑制剂及其制备方法
|
CN101175734B
(zh)
*
|
2005-05-12 |
2011-10-12 |
黄文林 |
一种作为抗肿瘤药物的喹唑啉衍生物及其制备方法
|
WO2006119673A1
(fr)
*
|
2005-05-12 |
2006-11-16 |
Wenlin Huang |
Procede de preparation de derives de quinazoline et application pour la fabrication pour le traitement d’une maladie tumorale
|
US8299076B2
(en)
|
2005-05-18 |
2012-10-30 |
Array Biopharma Inc. |
Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
|
KR20080037655A
(ko)
|
2005-07-21 |
2008-04-30 |
아스트라제네카 아베 |
신규 피페리딘 유도체
|
TW200738634A
(en)
|
2005-08-02 |
2007-10-16 |
Astrazeneca Ab |
New salt
|
TW200738658A
(en)
|
2005-08-09 |
2007-10-16 |
Astrazeneca Ab |
Novel compounds
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
US20090105212A1
(en)
|
2005-09-22 |
2009-04-23 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel adenine compound
|
WO2007034916A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
US20090192153A1
(en)
|
2005-09-22 |
2009-07-30 |
Dainippon Sumitomo Pharma Co., Ltd. a corporation of Japan |
Novel adenine compound
|
JPWO2007034817A1
(ja)
|
2005-09-22 |
2009-03-26 |
大日本住友製薬株式会社 |
新規アデニン化合物
|
WO2007034882A1
(ja)
|
2005-09-22 |
2007-03-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
GB0519879D0
(en)
|
2005-09-30 |
2005-11-09 |
Astrazeneca Ab |
Chemical process
|
JP5155171B2
(ja)
|
2005-10-06 |
2013-02-27 |
アストラゼネカ・アクチエボラーグ |
新規化合物
|
AU2006201635A1
(en)
*
|
2005-10-20 |
2007-05-10 |
Ludwig Institute For Cancer Research |
Novel inhibitors and methods for their preparation
|
PL1945631T3
(pl)
|
2005-10-28 |
2012-12-31 |
Astrazeneca Ab |
Pochodne 4-(3-aminopirazolo)pirymidyny do stosowania jako inhibitory kinazy tyrozynowej do leczenia raka
|
EP3173084B1
(en)
|
2005-11-11 |
2019-10-23 |
Boehringer Ingelheim International GmbH |
Quinazoline derivatives for the treatment of cancer diseases
|
CA2632194C
(en)
|
2005-11-15 |
2012-01-03 |
Array Biopharma Inc. |
N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
|
TW200730512A
(en)
|
2005-12-12 |
2007-08-16 |
Astrazeneca Ab |
Novel compounds
|
EP1979001B1
(en)
|
2005-12-13 |
2012-04-11 |
Medimmune Limited |
Binding proteins specific for insulin-like growth factors and uses thereof
|
ATE545637T1
(de)
|
2005-12-15 |
2012-03-15 |
Astrazeneca Ab |
Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
|
US20070213319A1
(en)
*
|
2006-01-11 |
2007-09-13 |
Angion Biomedica Corporation |
Modulators of hepatocyte growth factor/c-Met activity
|
US20070231298A1
(en)
*
|
2006-03-31 |
2007-10-04 |
Cell Genesys, Inc. |
Cytokine-expressing cancer immunotherapy combinations
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CN101454284A
(zh)
|
2006-05-26 |
2009-06-10 |
阿斯利康(瑞典)有限公司 |
联芳基或芳基-杂芳基取代的吲哚类化合物
|
JP2009542778A
(ja)
*
|
2006-07-13 |
2009-12-03 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
Mtkiキナゾリン誘導体
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
DE102006037478A1
(de)
|
2006-08-10 |
2008-02-14 |
Merck Patent Gmbh |
2-(Heterocyclylbenzyl)-pyridazinonderivate
|
KR101438245B1
(ko)
|
2006-08-23 |
2014-09-04 |
쿠도스 파마슈티칼스 리미티드 |
Mtor 억제제로서의 2-메틸모르폴린 피리도-, 피라조- 및 피리미도-피리미딘 유도체
|
EP2061772A4
(en)
*
|
2006-09-11 |
2011-06-29 |
Curis Inc |
MULTIFUNCTIONAL SMALL MOLECULES AS PROLIFERATION-ACTIVE ACTIVE SUBSTANCES
|
AU2007296745B2
(en)
*
|
2006-09-11 |
2011-12-01 |
Curis, Inc. |
Quinazoline based EGFR inhibitors
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
CN101535279B
(zh)
*
|
2006-09-11 |
2015-05-20 |
柯瑞斯公司 |
含锌结合基的喹唑啉基egfr抑制剂
|
CA2663599A1
(en)
*
|
2006-09-18 |
2008-03-27 |
Boehringer Ingelheim International Gmbh |
Method for treating cancer harboring egfr mutations
|
JP2010504949A
(ja)
|
2006-09-29 |
2010-02-18 |
アストラゼネカ アクチボラグ |
Zd6474とベバシズマブの癌療法のための組合せ
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
TW200825084A
(en)
|
2006-11-14 |
2008-06-16 |
Astrazeneca Ab |
New compounds 521
|
US7799954B2
(en)
|
2006-11-17 |
2010-09-21 |
Abraxis Bioscience, Llc |
Dicarbonyl derivatives and methods of use
|
TW200831528A
(en)
|
2006-11-30 |
2008-08-01 |
Astrazeneca Ab |
Compounds
|
CA2672446A1
(en)
|
2006-12-19 |
2008-06-26 |
Astrazeneca Ab |
Quinuclidinol derivatives as muscarinic receptor antagonists
|
CL2008000191A1
(es)
|
2007-01-25 |
2008-08-22 |
Astrazeneca Ab |
Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
|
WO2008095847A1
(de)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
|
US20080190689A1
(en)
*
|
2007-02-12 |
2008-08-14 |
Ballard Ebbin C |
Inserts for engine exhaust systems
|
PE20081887A1
(es)
|
2007-03-20 |
2009-01-16 |
Dainippon Sumitomo Pharma Co |
Nuevo compuesto de adenina
|
WO2008114819A1
(ja)
|
2007-03-20 |
2008-09-25 |
Dainippon Sumitomo Pharma Co., Ltd. |
新規アデニン化合物
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
DE102007025718A1
(de)
|
2007-06-01 |
2008-12-04 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102007025717A1
(de)
|
2007-06-01 |
2008-12-11 |
Merck Patent Gmbh |
Arylether-pyridazinonderivate
|
DE102007026341A1
(de)
|
2007-06-06 |
2008-12-11 |
Merck Patent Gmbh |
Benzoxazolonderivate
|
UA100983C2
(ru)
|
2007-07-05 |
2013-02-25 |
Астразенека Аб |
Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
|
DE102007032507A1
(de)
|
2007-07-12 |
2009-04-02 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DK2185562T3
(en)
|
2007-07-27 |
2016-02-22 |
Janssen Pharmaceutica Nv |
PYRROLOPYRIMIDINES SUITABLE FOR TREATING PROLIFERATIVE DISEASES
|
DE102007038957A1
(de)
|
2007-08-17 |
2009-02-19 |
Merck Patent Gmbh |
6-Thioxo-pyridazinderivate
|
DE102007041115A1
(de)
|
2007-08-30 |
2009-03-05 |
Merck Patent Gmbh |
Thiadiazinonderivate
|
US8119616B2
(en)
*
|
2007-09-10 |
2012-02-21 |
Curis, Inc. |
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
NZ584160A
(en)
|
2007-10-04 |
2011-05-27 |
Astrazeneca Ab |
Steroidal [3,2-c] pyrazole compounds, with glucocorticoid activity
|
SI2201012T1
(sl)
|
2007-10-11 |
2014-10-30 |
Astrazeneca Ab |
Derivati pirolo(2,3-D)pirimidina kot inhibitorji proteina kinaze B
|
US8080558B2
(en)
|
2007-10-29 |
2011-12-20 |
Natco Pharma Limited |
4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
|
JP5421925B2
(ja)
|
2007-12-19 |
2014-02-19 |
ジェネンテック, インコーポレイテッド |
5−アニリノイミダゾピリジン及び使用の方法
|
US8092804B2
(en)
|
2007-12-21 |
2012-01-10 |
Medimmune Limited |
Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
|
DE102007061963A1
(de)
|
2007-12-21 |
2009-06-25 |
Merck Patent Gmbh |
Pyridazinonderivate
|
RU2490278C2
(ru)
|
2007-12-21 |
2013-08-20 |
Медиммун Лимитед |
ЭЛЕМЕНТ, СВЯЗЫВАЮЩИЙСЯ С α-РЕЦЕПТОРОМ ИНТЕРЛЕЙКИНА-4 (IL-4Rα)-173
|
EP2220092B1
(en)
|
2007-12-21 |
2012-06-06 |
Genentech, Inc. |
Azaindolizines and methods of use
|
CA2712367C
(en)
*
|
2008-01-17 |
2016-01-19 |
Bayer Schering Pharma Aktiengesellschaft |
Sulphoximine-substituted quinazoline derivatives as immunomodulators, their preparation and use as medicaments
|
AU2009211523B2
(en)
|
2008-02-07 |
2014-03-13 |
Boehringer Ingelheim International Gmbh |
Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
|
KR20100135754A
(ko)
*
|
2008-02-21 |
2010-12-27 |
아스트라제네카 아베 |
병용 요법 238
|
CN101952287B
(zh)
|
2008-02-28 |
2013-11-27 |
默克专利有限公司 |
蛋白激酶抑制剂及其应用
|
DE102008019907A1
(de)
|
2008-04-21 |
2009-10-22 |
Merck Patent Gmbh |
Pyridazinonderivate
|
JP5739802B2
(ja)
|
2008-05-13 |
2015-06-24 |
アストラゼネカ アクチボラグ |
4−(3−クロロ−2−フルオロアニリノ)−7−メトキシ−6−{[1−(n−メチルカルバモイルメチル)ピペリジン−4−イル]オキシ}キナゾリンのフマル酸塩
|
CA2721065C
(en)
|
2008-05-27 |
2016-09-27 |
Astrazeneca Ab |
Phenoxypyridinylamide derivatives and their use as pde4 inhibitors
|
DE102008025750A1
(de)
|
2008-05-29 |
2009-12-03 |
Merck Patent Gmbh |
Dihydropyrazolderivate
|
DE102008028905A1
(de)
|
2008-06-18 |
2009-12-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
|
DE102008029734A1
(de)
|
2008-06-23 |
2009-12-24 |
Merck Patent Gmbh |
Thiazolyl-piperidinderivate
|
US8426430B2
(en)
*
|
2008-06-30 |
2013-04-23 |
Hutchison Medipharma Enterprises Limited |
Quinazoline derivatives
|
CN102137843A
(zh)
|
2008-07-01 |
2011-07-27 |
健泰科生物技术公司 |
作为mek激酶抑制剂的异吲哚酮衍生物及其使用方法
|
TWI461423B
(zh)
|
2008-07-02 |
2014-11-21 |
Astrazeneca Ab |
用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
|
CA2733153C
(en)
|
2008-08-08 |
2016-11-08 |
Boehringer Ingelheim International Gmbh |
Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
|
DE102008037790A1
(de)
|
2008-08-14 |
2010-02-18 |
Merck Patent Gmbh |
Bicyclische Triazolderivate
|
DE102008038221A1
(de)
|
2008-08-18 |
2010-02-25 |
Merck Patent Gmbh |
7-Azaindolderivate
|
CN101659657B
(zh)
*
|
2008-08-29 |
2014-05-14 |
北大方正集团有限公司 |
氰基取代的喹啉衍生物及其制备方法和用途
|
CN101659658B
(zh)
*
|
2008-08-29 |
2014-04-02 |
北大方正集团有限公司 |
氰基取代的喹啉衍生物
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
DE102008052943A1
(de)
|
2008-10-23 |
2010-04-29 |
Merck Patent Gmbh |
Azaindolderivate
|
WO2010067102A1
(en)
|
2008-12-09 |
2010-06-17 |
Astrazeneca Ab |
Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
|
KR101849059B1
(ko)
|
2008-12-11 |
2018-04-13 |
악센투아 파마슈투칼스 아베 |
제니스테인의 결정성 형태
|
US7863325B2
(en)
|
2008-12-11 |
2011-01-04 |
Axcentua Pharmaceuticals Ab |
Crystalline genistein sodium salt dihydrate
|
US20100152197A1
(en)
|
2008-12-15 |
2010-06-17 |
Astrazeneca Ab |
(4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
|
EP2367821B1
(en)
|
2008-12-17 |
2015-09-16 |
Merck Patent GmbH |
C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
|
JP2012512871A
(ja)
|
2008-12-18 |
2012-06-07 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
三環式アザインドール
|
DE102008063667A1
(de)
|
2008-12-18 |
2010-07-01 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
DE102008062825A1
(de)
|
2008-12-23 |
2010-06-24 |
Merck Patent Gmbh |
3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
|
DE102008062826A1
(de)
|
2008-12-23 |
2010-07-01 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009003954A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Pyridazinonderivate
|
DE102009003975A1
(de)
|
2009-01-07 |
2010-07-08 |
Merck Patent Gmbh |
Benzothiazolonderivate
|
DE102009004061A1
(de)
|
2009-01-08 |
2010-07-15 |
Merck Patent Gmbh |
Pyridazinonderivate
|
TW201920110A
(zh)
|
2009-01-16 |
2019-06-01 |
美商艾克塞里克斯公司 |
包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
|
IL271761B
(en)
|
2009-02-05 |
2022-09-01 |
Immunogen Inc |
(12as)-8-methoxy-9-benzyloxy-11,12,12a,13-tetrahydro-6h-indolo[2,1-c][1,4]benzodiazepine-6-one, 4-benzyloxy-5-methoxy -2-nitrobenzoic acid and a process for their preparation
|
WO2010089580A1
(en)
|
2009-02-06 |
2010-08-12 |
Astrazeneca Ab |
Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
|
PE20120603A1
(es)
|
2009-02-10 |
2012-06-14 |
Astrazeneca Ab |
Derivados de triazolo[4,3-b]piridazina y sus usos para el cancer de prostata
|
GB0905127D0
(en)
|
2009-03-25 |
2009-05-06 |
Pharminox Ltd |
Novel prodrugs
|
UY32520A
(es)
|
2009-04-03 |
2010-10-29 |
Astrazeneca Ab |
Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
|
US8389580B2
(en)
|
2009-06-02 |
2013-03-05 |
Duke University |
Arylcyclopropylamines and methods of use
|
US20100317593A1
(en)
|
2009-06-12 |
2010-12-16 |
Astrazeneca Ab |
2,3-dihydro-1h-indene compounds
|
EP2451445B1
(en)
|
2009-07-06 |
2019-04-03 |
Boehringer Ingelheim International GmbH |
Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
|
GB0913342D0
(en)
|
2009-07-31 |
2009-09-16 |
Astrazeneca Ab |
Compounds - 801
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
ES2535176T3
(es)
|
2009-09-28 |
2015-05-06 |
Qilu Pharmaceutical Co., Ltd |
Derivados de 4-(anilino sustituido)quinazolina como inhibidores de la tirosina quinasa
|
DE102009043260A1
(de)
|
2009-09-28 |
2011-04-28 |
Merck Patent Gmbh |
Pyridinyl-imidazolonderivate
|
WO2011039528A1
(en)
|
2009-10-02 |
2011-04-07 |
Astrazeneca Ab |
2-pyridone compounds used as inhibitors of neutrophil elastase
|
DE102009049679A1
(de)
|
2009-10-19 |
2011-04-21 |
Merck Patent Gmbh |
Pyrazolopyrimidinderivate
|
WO2011048409A1
(en)
|
2009-10-20 |
2011-04-28 |
Astrazeneca Ab |
Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
|
US8399460B2
(en)
|
2009-10-27 |
2013-03-19 |
Astrazeneca Ab |
Chromenone derivatives
|
WO2011062550A1
(en)
|
2009-11-18 |
2011-05-26 |
Astrazeneca Ab |
Benzoimidazole compounds and uses thereof
|
MX343747B
(es)
|
2009-11-24 |
2016-11-22 |
Medimmune Ltd |
Agentes de union diana contra b7-h1.
|
EP2507237A1
(en)
|
2009-12-03 |
2012-10-10 |
Dainippon Sumitomo Pharma Co., Ltd. |
Imidazoquinolines which act via toll - like receptors (tlr)
|
SG181570A1
(en)
|
2009-12-14 |
2012-07-30 |
Merck Patent Gmbh |
Inhibitors of sphingosine kinase
|
DE102009058280A1
(de)
|
2009-12-14 |
2011-06-16 |
Merck Patent Gmbh |
Thiazolderivate
|
MX2012006962A
(es)
|
2009-12-17 |
2012-07-17 |
Merck Patent Gmbh |
Inhibidores de la esfingosina quinasa.
|
CN103980338B
(zh)
|
2010-01-15 |
2017-04-26 |
苏州润新生物科技有限公司 |
蟾蜍灵衍生物、其药物组合物及用途
|
BR112012017884A2
(pt)
|
2010-01-19 |
2019-09-24 |
Astrazeneca Ab |
composto, composição farmacêutica, uso de um composto, derivado de pirazina, métodos para o tratamento ou prevenção, para promoção óssea, e, para tratar lesões ósseas em cânceres
|
WO2011095807A1
(en)
|
2010-02-07 |
2011-08-11 |
Astrazeneca Ab |
Combinations of mek and hh inhibitors
|
TW201129384A
(en)
|
2010-02-10 |
2011-09-01 |
Immunogen Inc |
CD20 antibodies and uses thereof
|
WO2011114148A1
(en)
|
2010-03-17 |
2011-09-22 |
Astrazeneca Ab |
4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
|
TWI406853B
(zh)
*
|
2010-04-07 |
2013-09-01 |
Dev Center Biotechnology |
Egfr與vegfr-2雙重抑制劑及其用途與製法
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
KR101217526B1
(ko)
*
|
2010-06-11 |
2013-01-02 |
한미사이언스 주식회사 |
아마이드 유도체 또는 이의 약학적으로 허용 가능한 염을 포함하는 약제학적 조성물
|
GB201009801D0
(en)
|
2010-06-11 |
2010-07-21 |
Astrazeneca Ab |
Compounds 950
|
WO2012000182A1
(en)
*
|
2010-06-30 |
2012-01-05 |
Hutchison Medipharma Limited |
Quinazoline compounds
|
UY33539A
(es)
|
2010-08-02 |
2012-02-29 |
Astrazeneca Ab |
Compuestos químicos alk
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
DE102010034699A1
(de)
|
2010-08-18 |
2012-02-23 |
Merck Patent Gmbh |
Pyrimidinderivate
|
WO2012027957A1
(en)
|
2010-08-28 |
2012-03-08 |
Suzhou Neupharma Co., Ltd. |
Bufalin derivatives, pharmaceutical compositions and use thereof
|
CA2812061A1
(en)
|
2010-09-22 |
2012-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of the gpr119 receptor and the treatment of disorders related thereto
|
GB201016442D0
(en)
|
2010-09-30 |
2010-11-17 |
Pharminox Ltd |
Novel acridine derivatives
|
DE102010048800A1
(de)
|
2010-10-20 |
2012-05-10 |
Merck Patent Gmbh |
Chinoxalinderivate
|
DE102010049595A1
(de)
|
2010-10-26 |
2012-04-26 |
Merck Patent Gmbh |
Chinazolinderivate
|
US20130267532A1
(en)
|
2010-11-19 |
2013-10-10 |
Shinya Tosaki |
Cyclic amide compounds and their use in the treatment of disease
|
WO2012066335A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Phenol compounds als toll -like receptor 7 agonists
|
WO2012066336A1
(en)
|
2010-11-19 |
2012-05-24 |
Astrazeneca Ab |
Benzylamine compounds as toll -like receptor 7 agonists
|
WO2012067269A1
(en)
|
2010-11-19 |
2012-05-24 |
Dainippon Sumitomo Pharma Co., Ltd. |
Aminoalkoxyphenyl compounds and their use in the treatment of disease
|
EP2651937B8
(en)
|
2010-12-16 |
2016-07-13 |
Sumitomo Dainippon Pharma Co., Ltd. |
Imidazo[4,5-c]quinolin-1-yl derivative useful in therapy
|
WO2012080730A1
(en)
|
2010-12-17 |
2012-06-21 |
Astrazeneca Ab |
Purine derivatives
|
AU2011347354A1
(en)
|
2010-12-20 |
2013-08-01 |
Medimmune Limited |
Anti-IL-18 antibodies and their uses
|
EP2670763B1
(en)
|
2011-02-02 |
2018-08-01 |
Suzhou Neupharma Co., Ltd |
Certain chemical entities, compositions, and methods
|
US9534000B2
(en)
|
2011-02-15 |
2017-01-03 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives and methods of preparation
|
CA2827172C
(en)
|
2011-02-17 |
2019-02-26 |
Cancer Therapeutics Crc Pty Limited |
Selective fak inhibitors
|
CA2827171C
(en)
|
2011-02-17 |
2019-04-09 |
Cancer Therapeutics Crc Pty Limited |
Fak inhibitors
|
KR20220031732A
(ko)
|
2011-03-04 |
2022-03-11 |
뉴젠 세러퓨틱스 인코포레이티드 |
알킨 치환된 퀴나졸린 화합물 및 그것의 사용 방법
|
GB201104267D0
(en)
|
2011-03-14 |
2011-04-27 |
Cancer Rec Tech Ltd |
Pyrrolopyridineamino derivatives
|
UY34013A
(es)
|
2011-04-13 |
2012-11-30 |
Astrazeneca Ab |
?compuestos de cromenona con actividad anti-tumoral?.
|
WO2012155339A1
(zh)
|
2011-05-17 |
2012-11-22 |
江苏康缘药业股份有限公司 |
4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
|
KR101317809B1
(ko)
|
2011-06-07 |
2013-10-16 |
한미약품 주식회사 |
암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
|
WO2012175991A1
(en)
|
2011-06-24 |
2012-12-27 |
Pharminox Limited |
Fused pentacyclic anti - proliferative compounds
|
WO2013003697A1
(en)
|
2011-06-30 |
2013-01-03 |
Trustees Of Boston University |
Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
|
WO2013008002A1
(en)
|
2011-07-12 |
2013-01-17 |
Astrazeneca Ab |
N- (6- ( (2r,3s) -3,4-dihydroxybutan-2-yloxy) -2- (4 - fluorobenzylthio) pyrimidin- 4 - yl) -3- methylazetidine- 1 - sulfonamide as chemokine receptor modulator
|
MY161925A
(en)
|
2011-07-27 |
2017-05-15 |
Astrazeneca Ab |
2 - (2, 4, 5 - substituted -anilino) pyrimidine derivatives as egfr modulators useful for treating cancer
|
DE102011111400A1
(de)
|
2011-08-23 |
2013-02-28 |
Merck Patent Gmbh |
Bicyclische heteroaromatische Verbindungen
|
JP6002223B2
(ja)
|
2011-08-26 |
2016-10-05 |
ニューファーマ, インコーポレイテッド |
特定の化学的実体、組成物、および方法
|
CN104080335B
(zh)
|
2011-09-01 |
2017-06-09 |
钱向平 |
某些化学实体、组合物及方法
|
CA2848506C
(en)
|
2011-09-14 |
2020-07-21 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US9249110B2
(en)
|
2011-09-21 |
2016-02-02 |
Neupharma, Inc. |
Substituted quinoxalines as B-raf kinase inhibitors
|
US20140235573A1
(en)
|
2011-09-29 |
2014-08-21 |
The University Of Liverpool |
Prevention and/or treatment of cancer and/or cancer metastasis
|
WO2013049701A1
(en)
|
2011-09-30 |
2013-04-04 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
US20130178520A1
(en)
|
2011-12-23 |
2013-07-11 |
Duke University |
Methods of treatment using arylcyclopropylamine compounds
|
US9670180B2
(en)
|
2012-01-25 |
2017-06-06 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
ES2655264T3
(es)
|
2012-01-28 |
2018-02-19 |
Merck Patent Gmbh |
Derivados de triazolo[4,5-d]pirimidina
|
CA2863985C
(en)
|
2012-02-09 |
2020-08-11 |
Merck Patent Gmbh |
Furo [3,2-b] - and thieno [3,2-b] pyridine derivatives as tbk1 and ikk inhibitors
|
NZ630170A
(en)
|
2012-02-09 |
2016-03-31 |
Merck Patent Gmbh |
Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
|
US9073944B2
(en)
|
2012-02-21 |
2015-07-07 |
Merck Patent Gmbh |
Cyclic diaminopyrimidine derivatives
|
CA2863717C
(en)
|
2012-02-21 |
2021-09-28 |
Lars Burgdorf |
Furopyridine derivatives
|
WO2013124026A1
(en)
|
2012-02-21 |
2013-08-29 |
Merck Patent Gmbh |
8 - substituted 2 -amino - [1,2,4] triazolo [1, 5 -a] pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors
|
AU2013230286B2
(en)
|
2012-03-07 |
2016-12-22 |
Merck Patent Gmbh |
Triazolopyrazine derivatives
|
US9193718B2
(en)
|
2012-03-26 |
2015-11-24 |
Fujian Institute Of Research On The Structure Of Matter, Chinese Academy Of Sciences |
Quinazoline derivative and application thereof
|
US9120805B2
(en)
|
2012-03-28 |
2015-09-01 |
Merck Patent Gmbh |
Substituted pyrrolo[1,2-A]pyrazin-1-ones and pyrazolo[1,5-A]pyrazin-4-ones as inhibitors of tankyrase and poly(ADP-ribose)polymerase activity
|
WO2013144532A1
(en)
|
2012-03-30 |
2013-10-03 |
Astrazeneca Ab |
3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
|
KR101674784B1
(ko)
|
2012-04-05 |
2016-11-09 |
에프. 호프만-라 로슈 아게 |
인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도
|
WO2013165924A1
(en)
|
2012-04-29 |
2013-11-07 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
RS55062B1
(sr)
|
2012-05-04 |
2016-12-30 |
Merck Patent Gmbh |
Pirolotriazinon derivati
|
EP2859017B1
(en)
|
2012-06-08 |
2019-02-20 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
GB201211021D0
(en)
|
2012-06-21 |
2012-08-01 |
Cancer Rec Tech Ltd |
Pharmaceutically active compounds
|
DK2863955T3
(en)
|
2012-06-26 |
2017-01-23 |
Sutro Biopharma Inc |
MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
|
US9624264B2
(en)
|
2012-07-24 |
2017-04-18 |
Merck Patent Gmbh |
Hydroxystatin derivatives for the treatment of arthrosis
|
US9725462B2
(en)
|
2012-08-07 |
2017-08-08 |
Merck Patent Gmbh |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
KR102083154B1
(ko)
|
2012-08-08 |
2020-03-02 |
메르크 파텐트 게엠베하 |
(아자―)이소퀴놀리논 유도체
|
US20160009686A1
(en)
|
2012-08-17 |
2016-01-14 |
Cancer Therapeutics Crc Pty Limited |
Vegfr3 inhibitors
|
WO2014031566A1
(en)
|
2012-08-22 |
2014-02-27 |
Immunogen, Inc. |
Cytotoxic benzodiazepine derivatives
|
EP3584255B1
(en)
|
2012-08-31 |
2022-02-16 |
Sutro Biopharma, Inc. |
Modified amino acids comprising an azido group
|
WO2014041349A1
(en)
|
2012-09-12 |
2014-03-20 |
Cancer Therapeutics Crc Pty Ltd |
Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
|
EP2897618B1
(en)
|
2012-09-24 |
2021-11-17 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
KR102200628B1
(ko)
|
2012-09-26 |
2021-01-08 |
메르크 파텐트 게엠베하 |
Parp 억제제로서의 퀴나졸리논 유도체
|
AU2013334493B2
(en)
|
2012-10-26 |
2018-11-29 |
The University Of Queensland |
Use of endocytosis inhibitors and antibodies for cancer therapy
|
AU2013337616B2
(en)
|
2012-11-05 |
2019-03-21 |
Gmdx Co Pty Ltd |
Methods for determining the cause of somatic mutagenesis
|
EP2916838B1
(en)
|
2012-11-12 |
2019-03-13 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
AU2013347232A1
(en)
|
2012-11-16 |
2015-07-02 |
Merck Patent Gmbh |
3-aminocyclopentane carboxamide derivatives
|
KR20140096571A
(ko)
|
2013-01-28 |
2014-08-06 |
한미약품 주식회사 |
1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
|
PT3381917T
(pt)
|
2013-01-31 |
2021-10-27 |
Bellus Health Cough Inc |
Compostos imidazopiridina e suas utilizações
|
ES2612982T3
(es)
|
2013-02-25 |
2017-05-19 |
Merck Patent Gmbh |
Derivados de 2-amino-3,4-dihidroquinazolina y su aplicación como inhibidores de la catepsina D
|
US9901647B2
(en)
|
2013-02-28 |
2018-02-27 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
EP2961434A2
(en)
|
2013-02-28 |
2016-01-06 |
ImmunoGen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
ES2614872T3
(es)
|
2013-03-05 |
2017-06-02 |
Merck Patent Gmbh |
Derivados de 9-(aril o heteroaril)-2-(pirazolilo, pirrolidinilo o ciclopentilo) aminopurina como agentes anticancer
|
JP2016513735A
(ja)
|
2013-03-15 |
2016-05-16 |
マグシューティクス,インコーポレイテッド |
癌のためのマグネシウム組成物およびその使用
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
WO2014194030A2
(en)
|
2013-05-31 |
2014-12-04 |
Immunogen, Inc. |
Conjugates comprising cell-binding agents and cytotoxic agents
|
US20160115146A1
(en)
|
2013-06-07 |
2016-04-28 |
Universite Catholique De Louvain |
3-carboxy substituted coumarin derivatives with a potential utility for the treatment of cancer diseases
|
EP3013424A4
(en)
|
2013-06-25 |
2017-03-29 |
University of Canberra |
Methods and compositions for modulating cancer stem cells
|
US9764039B2
(en)
|
2013-07-10 |
2017-09-19 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
EP3035936B1
(en)
|
2013-08-23 |
2019-03-13 |
NeuPharma, Inc. |
Certain chemical entities, compositions, and methods
|
EP3039424B1
(en)
|
2013-08-28 |
2020-07-29 |
Crown Bioscience, Inc. (Taicang) |
Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same
|
ES2851724T3
(es)
|
2013-09-18 |
2021-09-08 |
Epiaxis Therapeutics Pty Ltd |
Modulación de células madre
|
EP3052660A4
(en)
|
2013-10-01 |
2017-04-26 |
Queensland University Of Technology |
Kits and methods for diagnosis, screening, treatment and disease monitoring
|
US9840493B2
(en)
|
2013-10-11 |
2017-12-12 |
Sutro Biopharma, Inc. |
Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
|
US8986691B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US8980273B1
(en)
|
2014-07-15 |
2015-03-17 |
Kymab Limited |
Method of treating atopic dermatitis or asthma using antibody to IL4RA
|
US9242965B2
(en)
|
2013-12-31 |
2016-01-26 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
|
GB201403536D0
(en)
|
2014-02-28 |
2014-04-16 |
Cancer Rec Tech Ltd |
Inhibitor compounds
|
WO2015175750A1
(en)
|
2014-05-15 |
2015-11-19 |
The Methodist Hospital System |
Multivalent ligands targeting vegfr
|
CN105330653A
(zh)
*
|
2014-08-11 |
2016-02-17 |
石药集团中奇制药技术(石家庄)有限公司 |
喹唑啉衍生物
|
WO2016029262A1
(en)
|
2014-08-25 |
2016-03-03 |
University Of Canberra |
Compositions for modulating cancer stem cells and uses therefor
|
WO2016077881A1
(en)
|
2014-11-17 |
2016-05-26 |
The University Of Queensland |
Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
|
MA41179A
(fr)
|
2014-12-19 |
2017-10-24 |
Cancer Research Tech Ltd |
Composés inhibiteurs de parg
|
AU2016205361C1
(en)
|
2015-01-06 |
2021-04-08 |
Arena Pharmaceuticals, Inc. |
Methods of treating conditions related to the S1P1 receptor
|
GB201501870D0
(en)
|
2015-02-04 |
2015-03-18 |
Cancer Rec Tech Ltd |
Autotaxin inhibitors
|
GB201502020D0
(en)
|
2015-02-06 |
2015-03-25 |
Cancer Rec Tech Ltd |
Autotaxin inhibitory compounds
|
CA2976227C
(en)
|
2015-02-17 |
2023-10-24 |
Neupharma, Inc. |
Quinazoline derivatives and their use in treatment of cancer
|
GB201510019D0
(en)
|
2015-06-09 |
2015-07-22 |
Cancer Therapeutics Crc Pty Ltd |
Compounds
|
KR102603199B1
(ko)
|
2015-06-22 |
2023-11-16 |
아레나 파마슈티칼스, 인크. |
S1p1 수용체-관련 장애에서의 사용을 위한 (r)-2-(7-(4-시클로펜틸-3-(트리플루오로메틸)벤질옥시)-1,2,3,4-테트라히드로시클로-펜타[b]인돌-3-일)아세트산 (화합물 1)의 결정성 l-아르기닌 염
|
EP3957637B1
(en)
|
2015-08-04 |
2023-06-28 |
Aucentra Therapeutics Pty Ltd |
N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds
|
WO2017031551A1
(en)
|
2015-08-26 |
2017-03-02 |
Gmdx Co Pty Ltd |
Methods of detecting cancer recurrence
|
GB201516504D0
(en)
|
2015-09-17 |
2015-11-04 |
Astrazeneca Ab |
Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer
|
GB201519568D0
(en)
|
2015-11-05 |
2015-12-23 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
SG10202008046UA
(en)
|
2015-12-23 |
2020-09-29 |
Univ Queensland Technology |
Nucleic acid oligomers and uses therefor
|
RU2018130757A
(ru)
|
2016-01-27 |
2020-02-27 |
Сутро Биофарма, Инк. |
Конъюгаты антитела к cd74, композиции, содержащие конъюгаты антитела к cd74, и способы использования конъюгатов антитела к cd74
|
WO2017132728A1
(en)
|
2016-02-01 |
2017-08-10 |
University Of Canberra |
Proteinaceous compounds and uses therefor
|
GB201604182D0
(en)
|
2016-03-11 |
2016-04-27 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
JP2019512512A
(ja)
|
2016-03-21 |
2019-05-16 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
シンノリン−4−アミン化合物およびその癌治療への使用
|
MA44603A
(fr)
|
2016-04-07 |
2019-02-13 |
Astrazeneca Ab |
Oxyde de n,n-diméthyl-3-[[5-(3-méthyl-2-oxo-1-tétrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine utilisé comme modulateur de la protéine kinase atm (ataxia telangiectasia mutated) pour traiter le cancer
|
CN105853434A
(zh)
*
|
2016-04-13 |
2016-08-17 |
李春 |
一种治疗正畸儿童牙龈炎的药物组合物
|
PL3442535T3
(pl)
|
2016-04-15 |
2022-10-24 |
Cancer Research Technology Limited |
Związki heterocykliczne jako inhibitory kinazy ret
|
GB2554333A
(en)
|
2016-04-26 |
2018-04-04 |
Big Dna Ltd |
Combination therapy
|
GB201608227D0
(en)
|
2016-05-11 |
2016-06-22 |
Astrazeneca Ab |
Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
|
WO2018022992A1
(en)
|
2016-07-29 |
2018-02-01 |
Flx Bio, Inc. |
Chemokine receptor modulators and uses thereof
|
CA3033370A1
(en)
|
2016-08-15 |
2018-02-22 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
CA3035081A1
(en)
|
2016-09-02 |
2018-03-08 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
AU2017332839B2
(en)
|
2016-09-22 |
2021-11-11 |
Cancer Research Technology Limited |
Preparation and uses of pyrimidinone derivatives
|
GB201617103D0
(en)
|
2016-10-07 |
2016-11-23 |
Cancer Research Technology Limited |
Compound
|
CA3045517A1
(en)
|
2016-12-05 |
2018-06-14 |
Apros Therapeutics, Inc. |
Pyrimidine compounds containing acidic groups
|
US10786502B2
(en)
|
2016-12-05 |
2020-09-29 |
Apros Therapeutics, Inc. |
Substituted pyrimidines containing acidic groups as TLR7 modulators
|
JP6883653B2
(ja)
|
2016-12-20 |
2021-06-09 |
アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag |
アミノ−トリアゾロピリジン化合物および癌の治療におけるその使用
|
CA3051604A1
(en)
|
2017-02-01 |
2018-08-09 |
Aucentra Therapeutics Pty Ltd |
Derivatives of n-cycloalkyl/heterocycloalkyl-4-(imidazo [1,2-a]pyridine)pyrimidin-2-amine as therapeutic agents
|
WO2018162625A1
(en)
|
2017-03-09 |
2018-09-13 |
Truly Translational Sweden Ab |
Prodrugs of sulfasalazine, pharmaceutical compositions thereof and their use in the treatment of autoimmune disease
|
JOP20190209A1
(ar)
|
2017-03-16 |
2019-09-12 |
Astrazeneca Ab |
مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان
|
GB201704325D0
(en)
|
2017-03-17 |
2017-05-03 |
Argonaut Therapeutics Ltd |
Compounds
|
GB201705971D0
(en)
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
CN108864079B
(zh)
|
2017-05-15 |
2021-04-09 |
深圳福沃药业有限公司 |
一种三嗪化合物及其药学上可接受的盐
|
EP4371562A2
(en)
|
2017-05-26 |
2024-05-22 |
Cancer Research Technology Limited |
2-quinolone derived inhibitors of bcl6
|
WO2018215801A1
(en)
|
2017-05-26 |
2018-11-29 |
Cancer Research Technology Limited |
Benzimidazolone derived inhibitors of bcl6
|
US11883405B2
(en)
|
2017-05-31 |
2024-01-30 |
Amplio Pharma Ab |
Pharmaceutical composition comprising a combination of methotrexate and novobiocin, and the use of said composition in therapy
|
AU2017422200B2
(en)
|
2017-07-05 |
2022-11-24 |
E.P.O.S Iasis Research And Development Limited |
Multifunctional conjugates
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
SI3661941T1
(sl)
|
2017-08-01 |
2023-04-28 |
Merck Patent Gmbh |
Tiazolopiridinski derivati kot antagonisti adenozinskih receptorjev
|
CN111278840B
(zh)
|
2017-08-18 |
2023-11-17 |
癌症研究科技有限公司 |
吡咯并[2,3-b]吡啶化合物及其治疗癌症的用途
|
TWI791593B
(zh)
|
2017-08-21 |
2023-02-11 |
德商馬克專利公司 |
做為腺苷受體拮抗劑之苯并咪唑衍生物
|
DK3672951T3
(da)
|
2017-08-21 |
2023-11-20 |
Merck Patent Gmbh |
Quinoxalinderivater som adenosinreceptorantagonister
|
KR20200051802A
(ko)
|
2017-09-18 |
2020-05-13 |
서트로 바이오파마, 인크. |
항-엽산 수용체 알파 항체 접합체 및 이의 용도
|
CN111344293A
(zh)
|
2017-09-20 |
2020-06-26 |
阿斯利康(瑞典)有限公司 |
1,3-二氢咪唑并[4,5-c]噌啉-2-酮化合物及其在治疗癌症中的用途
|
TWI702205B
(zh)
|
2017-10-06 |
2020-08-21 |
俄羅斯聯邦商拜奧卡德聯合股份公司 |
表皮生長因子受體抑制劑
|
RU2020118594A
(ru)
|
2017-11-06 |
2021-12-09 |
Рапт Терапьютикс, Инк. |
Противораковые агенты
|
EP3489222A1
(en)
|
2017-11-23 |
2019-05-29 |
medac Gesellschaft für klinische Spezialpräparate mbH |
Sulfasalazine salts, production processes and uses
|
FI3488868T3
(fi)
|
2017-11-23 |
2023-10-20 |
Medac Ges Fuer Klinische Spezialpraeparate Mbh |
Suun kautta annettava sulfasalatsiinia ja/tai sulfasalatsiinin orgaanista suolaa sisältävä farmaseuttinen koostumus, valmistusmenetelmä ja käyttö
|
EP3740484A4
(en)
|
2018-01-15 |
2021-06-09 |
Aucentra Holdings Pty Ltd |
5- (PYRIMIDIN-4-YL) THIAZOL-2-YL-UREA DERIVATIVES AS THERAPEUTICS
|
GB201801128D0
(en)
|
2018-01-24 |
2018-03-07 |
Univ Oxford Innovation Ltd |
Compounds
|
SG11202007072RA
(en)
|
2018-01-26 |
2020-08-28 |
Rapt Therapeutics Inc |
Chemokine receptor modulators and uses thereof
|
CA3090528A1
(en)
|
2018-02-08 |
2019-08-15 |
Neupharma, Inc. |
Certain chemical entities, compositions, and methods
|
WO2019175093A1
(en)
|
2018-03-12 |
2019-09-19 |
Astrazeneca Ab |
Method for treating lung cancer
|
WO2019197842A1
(en)
|
2018-04-13 |
2019-10-17 |
Cancer Research Technology Limited |
Bcl6 inhibitors
|
BR112020024062A2
(pt)
|
2018-04-27 |
2021-02-09 |
Spruce Biosciences, Inc. |
métodos para o tratamento de tumores de restos adrenais de testículo e de ovário
|
AR114910A1
(es)
|
2018-06-04 |
2020-10-28 |
Apros Therapeutics Inc |
Compuestos de pirimidina que contienen grupos ácidos
|
GB201809102D0
(en)
|
2018-06-04 |
2018-07-18 |
Univ Oxford Innovation Ltd |
Compounds
|
EP3802544A1
(en)
|
2018-06-05 |
2021-04-14 |
RAPT Therapeutics, Inc. |
Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
|
GB201810092D0
(en)
|
2018-06-20 |
2018-08-08 |
Ctxt Pty Ltd |
Compounds
|
GB201810581D0
(en)
|
2018-06-28 |
2018-08-15 |
Ctxt Pty Ltd |
Compounds
|
WO2020060944A1
(en)
|
2018-09-17 |
2020-03-26 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
RS65413B1
(sr)
|
2018-09-18 |
2024-05-31 |
Hoffmann La Roche |
Derivati hinazolina kao antitumorski agensi
|
US11084829B2
(en)
|
2018-09-24 |
2021-08-10 |
Rapt Therapeutics, Inc. |
Ubiquitin-specific-processing protease 7 (USP7) modulators and uses thereof
|
WO2020083856A1
(en)
|
2018-10-25 |
2020-04-30 |
Merck Patent Gmbh |
5-azaindazole derivatives as adenosine receptor antagonists
|
MX2021003901A
(es)
|
2018-10-25 |
2021-06-04 |
Merck Patent Gmbh |
Derivados de 5-azaindazol como antagonistas del receptor de adenosina.
|
GB201819126D0
(en)
|
2018-11-23 |
2019-01-09 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
EP3960858A4
(en)
|
2018-12-25 |
2023-02-15 |
Institute of Basic Medical Sciences Chinese Academy of Medical Sciences |
SMALL RNA DRUG USED TO PREVENT AND TREAT INFLAMMATION-RELATED DISEASES AND COMBINATIONS THEREOF
|
AR117844A1
(es)
|
2019-01-22 |
2021-09-01 |
Merck Patent Gmbh |
Derivados de tiazolopiridina como antagonistas del receptor de adenosina
|
JP2022524759A
(ja)
|
2019-03-07 |
2022-05-10 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Shp2アンタゴニストとしてのカルボキサミド-ピリミジン誘導体
|
CN111747950B
(zh)
|
2019-03-29 |
2024-01-23 |
深圳福沃药业有限公司 |
用于治疗癌症的嘧啶衍生物
|
CN113905787A
(zh)
|
2019-04-05 |
2022-01-07 |
斯托姆治疗有限公司 |
Mettl3抑制化合物
|
US11001561B2
(en)
|
2019-04-08 |
2021-05-11 |
Merck Patent Gmbh |
Pyrimidinone derivatives as SHP2 antagonists
|
GB201905328D0
(en)
|
2019-04-15 |
2019-05-29 |
Azeria Therapeutics Ltd |
Inhibitor compounds
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
SG11202112796YA
(en)
|
2019-05-21 |
2021-12-30 |
Voronoi Inc |
N-containing heteroaryl derivative and pharmaceutical composition comprising same as active ingredient for prevention or treatment of cancer
|
GB201908885D0
(en)
|
2019-06-20 |
2019-08-07 |
Storm Therapeutics Ltd |
Therapeutic compounds
|
CN114728910B
(zh)
|
2019-08-31 |
2024-05-14 |
上海奕拓医药科技有限责任公司 |
用于fgfr抑制剂的吡唑类衍生物及其制备方法
|
CA3147493A1
(en)
|
2019-09-20 |
2021-03-25 |
Jr. James Clifford Sutton |
4-substituted indole and indazole sulfonamido derivatives as parg inhibitors
|
GB201913988D0
(en)
|
2019-09-27 |
2019-11-13 |
Celleron Therapeutics Ltd |
Novel treatment
|
GB201914860D0
(en)
|
2019-10-14 |
2019-11-27 |
Cancer Research Tech Ltd |
Inhibitor compounds
|
GB201915828D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915829D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
GB201915831D0
(en)
|
2019-10-31 |
2019-12-18 |
Cancer Research Tech Ltd |
Compounds, compositions and therapeutic uses thereof
|
JP2023506147A
(ja)
|
2019-12-02 |
2023-02-15 |
ストーム・セラピューティクス・リミテッド |
Mettl3阻害剤としてのポリヘテロ環式化合物
|
US20230095053A1
(en)
|
2020-03-03 |
2023-03-30 |
Sutro Biopharma, Inc. |
Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
|
GB202004960D0
(en)
|
2020-04-03 |
2020-05-20 |
Kinsenus Ltd |
Inhibitor compounds
|
GB202012969D0
(en)
|
2020-08-19 |
2020-09-30 |
Univ Of Oxford |
Inhibitor compounds
|
EP4219476A1
(en)
*
|
2020-09-25 |
2023-08-02 |
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. |
Salt of arylaminoquinazoline-containing compound, and preparation method therefor and use thereof
|
WO2022074379A1
(en)
|
2020-10-06 |
2022-04-14 |
Storm Therapeutics Limited |
Mettl3 inhibitory compounds
|
WO2022074391A1
(en)
|
2020-10-08 |
2022-04-14 |
Storm Therapeutics Limited |
Compounds inhibitors of mettl3
|
EP3992191A1
(en)
|
2020-11-03 |
2022-05-04 |
Deutsches Krebsforschungszentrum |
Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors
|
WO2022179608A1
(zh)
*
|
2021-02-25 |
2022-09-01 |
石药集团中奇制药技术(石家庄)有限公司 |
多靶点蛋白激酶抑制剂的用途
|
GB202102895D0
(en)
|
2021-03-01 |
2021-04-14 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
JP2024519205A
(ja)
|
2021-04-30 |
2024-05-09 |
セルジーン コーポレーション |
抗bcma抗体薬物コンジュゲート(adc)をガンマセクレターゼ阻害剤(gsi)と組み合わせて使用する併用療法
|
IL308163A
(en)
|
2021-05-03 |
2024-01-01 |
Merck Patent Gmbh |
FC antigen-binding conjugate drug fragments targeting HER2
|
CN117396463A
(zh)
|
2021-05-17 |
2024-01-12 |
怡诺安有限公司 |
用于预防或治疗癌症的苯甲酰胺衍生物、其制备方法和含有其作为活性成分的药物组合物
|
EP4346905A1
(en)
|
2021-05-25 |
2024-04-10 |
Merck Patent GmbH |
Egfr targeting fc antigen binding fragment-drug conjugates
|
GB202107907D0
(en)
|
2021-06-02 |
2021-07-14 |
Storm Therapeutics Ltd |
Combination therapies
|
GB202108383D0
(en)
|
2021-06-11 |
2021-07-28 |
Argonaut Therapeutics Ltd |
Compounds useful in the treatment or prevention of a prmt5-mediated disorder
|
WO2023057394A1
(en)
|
2021-10-04 |
2023-04-13 |
Forx Therapeutics Ag |
N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
|
AU2022359801A1
(en)
|
2021-10-04 |
2024-02-01 |
Forx Therapeutics Ag |
Parg inhibitory compounds
|
WO2023131690A1
(en)
|
2022-01-10 |
2023-07-13 |
Merck Patent Gmbh |
Substituted heterocycles as hset inhibitors
|
GB202202199D0
(en)
|
2022-02-18 |
2022-04-06 |
Cancer Research Tech Ltd |
Compounds
|
WO2023175184A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023175185A1
(en)
|
2022-03-17 |
2023-09-21 |
Forx Therapeutics Ag |
2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
|
WO2023186881A1
(en)
|
2022-03-29 |
2023-10-05 |
Baden-Württemberg Stiftung Ggmbh |
P38 map kinase inhibitors for use in the treatment of colorectal cancer
|
GB202204935D0
(en)
|
2022-04-04 |
2022-05-18 |
Cambridge Entpr Ltd |
Nanoparticles
|
WO2023196432A1
(en)
|
2022-04-06 |
2023-10-12 |
Rapt Therapeutics, Inc. |
Chemokine receptor modulators and uses thereof
|
GB202209404D0
(en)
|
2022-06-27 |
2022-08-10 |
Univ Of Sussex |
Compounds
|
TW202408589A
(zh)
|
2022-06-30 |
2024-03-01 |
美商舒卓生物製藥公司 |
抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物,及製造及使用抗ror1抗體及抗體結合物之方法
|
WO2024030825A1
(en)
|
2022-08-01 |
2024-02-08 |
Neupharma, Inc |
Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
|
GB202213163D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213164D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213167D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
GB202213162D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Prodrugs
|
GB202213166D0
(en)
|
2022-09-08 |
2022-10-26 |
Cambridge Entpr Ltd |
Novel compounds, compositions and therapeutic uses thereof
|
WO2024074497A1
(en)
|
2022-10-03 |
2024-04-11 |
Forx Therapeutics Ag |
Parg inhibitory compound
|
WO2024094963A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one and 7-amino-1-pyrimido[4,5-d]pyrimidin-2(1 h)-one derivatives as egfr inhibitors for the treatment of cancer
|
WO2024094962A1
(en)
|
2022-11-02 |
2024-05-10 |
Cancer Research Technology Limited |
Pyrido[2,3-d]pyrimidin-2-amine derivatives as egfr inhibitors for the treatment of cancer
|
WO2024099898A1
(en)
|
2022-11-07 |
2024-05-16 |
Merck Patent Gmbh |
Substituted bi-and tricyclic hset inhibitors
|
GB202218672D0
(en)
|
2022-12-12 |
2023-01-25 |
Storm Therapeutics Ltd |
Inhibitory compounds
|